Sustainable Supply Chains in Pharma and What They Mean for a Strong Organisation

November 20, 2026

Sustainable-Supply-Chains-in-Pharma-and-What-They-Mean-for-a-Strong-Organisation-v2Sustainable-Supply-Chains-in-Pharma-and-What-They-Mean-for-a-Strong-Organisation-v2

A sustainable supply chain in pharma manages environmental, social and ethical risks across suppliers, partners and the wider value chain. Done well, it protects supply and builds a stronger organisation. For investors, the evidence is in the data a company publishes and the targets it has had independently validated.

How Global Pharma Companies Navigate Uncertainty

What Is a Sustainable Supply Chain in Pharma?

How Global Pharma Companies Navigate Uncertainty

A sustainable supply chain in pharma considers the environmental, social and governance impact of every stage involved in bringing a medicine to patients. This extends beyond a pharmaceutical company's own manufacturing facilities to include the sourcing of raw materials and active pharmaceutical ingredients, contract manufacturing partners, logistics providers, packaging suppliers and other service providers.

The pharmaceutical supply chain has many layers. It starts with raw materials and active ingredients, often sourced across several countries. It continues through contract manufacturers and other partners, then packaging, storage and logistics to the hospital or pharmacy.

Each layer carries its own risks. Raw material suppliers face questions on energy, water and waste. Logistics partners face emissions and handling standards. Packaging suppliers face choices on materials and sourcing.

Sustainability means treating these risks as part of supply management, not as a separate project. A company sets expectations, checks that suppliers meet them and reports what it finds. The aim is a supplier base that is dependable and can show it.

The scope is wide. It covers how materials are sourced, how suppliers treat workers, how much energy and water they use and how openly they report.

Why-Does-Supply-Chain-Sustainability-Matter-Now

Why Does Supply Chain Sustainability Matter Now?

Why-Does-Supply-Chain-Sustainability-Matter-Now

Supply chain sustainability has become increasingly important as pharmaceutical companies face greater scrutiny from customers, regulators, investors and other stakeholders. Two developments are particularly relevant: the significant contribution of supply chains to corporate emissions and the growing expectation that suppliers demonstrate measurable sustainability progress.

Supply Chains Carry Most of a Company's Emissions

For many pharmaceutical companies, the largest share of their environmental footprint lies outside their direct operations. These indirect emissions, known as Scope 3 emissions, arise from activities across the value chain, including purchased goods and services, transportation, distribution and the use of sold products.

At Piramal Pharma, Scope 3 emissions accounted for approximately 85.5% of the reported greenhouse gas footprint in FY2025-26. This illustrates why progress on sustainability cannot be measured solely through improvements within manufacturing facilities. Engagement across the supplier ecosystem is equally important.

The scale of the challenge is also evident across the wider industry. According to Neuland Labs' June 2025 analysis, Scope 3 emissions account for 90% of total emissions at Novartis, 79.9% at Merck KGaA and 92% at GSK. These figures, cited by Neuland Labs, underline the importance of addressing emissions beyond a company's direct operational boundaries.

For pharmaceutical organisations, working with suppliers to improve emissions visibility and performance is therefore an important part of advancing their wider climate commitments. It is also why the pharma supply chain now sits at the centre of climate planning.

Customers Now Ask for Proof

Sustainability is also becoming an increasingly important consideration in commercial relationships. Pharmaceutical customers are looking beyond a supplier's ability to meet quality, cost and delivery requirements. They increasingly want evidence of responsible business practices and progress against environmental commitments.

In July 2023, the CEOs of several major pharmaceutical companies, including AstraZeneca, GSK, Merck, Novo Nordisk, Sanofi and Samsung Biologics, along with the Chairman of Roche, signed an open letter calling on suppliers to commit to common minimum climate and sustainability targets. The initiative sought to encourage greater consistency and collaboration in reducing emissions across the healthcare value chain.

The commercial implications are reflected in the 2023 CPHI Annual Report, as reported by Manufacturing Chemist. Approximately 80% of pharma executives surveyed expected sustainability metrics and goals to be integrated into contracts within two years. The report also found that 93% considered visibility into supply chain partners’ sustainability records important or extremely important.

Together, these developments point to a changing business environment. Pharmaceutical suppliers must increasingly demonstrate not just what they deliver, but how responsibly they deliver it.

How Does a Sustainable Supply Chain Build a Stronger Organisation?

A sustainable supply chain strengthens an organisation in three important ways: it supports reliable supply, helps maintain access to customer relationships and contracts, and provides investors with evidence of long-term risk management.

Reliable Supply

Suppliers that understand and meet shared environmental, social and governance standards are better positioned to maintain consistent practices and address potential risks. A structured approach to supplier assessment and engagement can also help organisations identify concerns before they affect business continuity.

This complements broader supply chain resilience measures, including visibility, flexibility and supplier diversification. Read more about how these priorities contribute to a resilient supply chain.

Access to Customers and Contracts

Sustainability metrics are becoming a condition of winning business. A supplier base that already meets them keeps Piramal eligible as customers apply the joint targets and contract terms described above.

Customers that must report their own Scope 3 emissions rely on supplier data to do so. A supplier that can provide it, and has an assessment on record, is easier to qualify.

Responsible sourcing in pharma is therefore a commercial requirement as well as an ethical one. Sustainability is part of how Piramal competes for customer contracts, not only part of how it reports.

Investor Confidence

Investors increasingly look for evidence that sustainability commitments are supported by clear targets, accountability and measurable progress. Independent validation of climate targets, transparent reporting and year-on-year performance provide a more meaningful basis for assessing an organisation's approach than broad commitments alone.

For Piramal Pharma, its FY2030 greenhouse gas reduction targets have been validated by the Science Based Targets initiative (SBTi). The Company has committed to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25%, against a FY2022 baseline.

Its FY2025-26 performance provides an indication of progress, with a 22.6% reduction in Scope 1 and 2 emissions compared with FY2022. Renewable energy accounted for 41% of total energy consumption during the year.

These measurable outcomes help demonstrate how sustainability objectives are being translated into organisational priorities and monitored over time.

How-Does-Piramal-Pharma-Manage-Its-Supply-Chain-Responsibly

How Does Piramal Pharma Manage Its Supply Chain Responsibly?

How-Does-Piramal-Pharma-Manage-Its-Supply-Chain-Responsibly

Piramal Pharma’s approach to responsible supply chain management combines supplier standards, risk-based assessments, measurable sustainability targets and ongoing engagement with business partners. The objective is to extend responsible business practices across the value chain while strengthening supplier capabilities. Together, these steps support sustainable pharmaceutical manufacturing across its network.

Standards and Assessments

Piramal Pharma’s Sustainable Procurement Policy and Supplier Code of Conduct establish expectations for suppliers across key environmental, social and governance areas. The Supplier Code of Conduct covers 100% of the Company’s suppliers, providing a common framework for responsible business practices.

The Company is also an active full member of the Pharmaceutical Supply Chain Initiative (PSCI), which promotes responsible business practices across the pharmaceutical and healthcare supply chain. Participation supports alignment with shared industry expectations and encourages collaboration on common sustainability priorities.

Supplier assessments form another important part of the framework. Piramal Pharma uses third-party assessments recognised within its supplier evaluation process to avoid unnecessary duplication of audits. Assessment frequency is determined by risk and can range from annually to once every three years.

This risk-based approach enables the Company to focus attention on areas requiring closer oversight while encouraging continuous improvement across its supplier network. For a step-by-step view of how suppliers are screened and audited, see our guide to responsible sourcing in pharma.

Targets and Results

Piramal Pharma’s sustainability commitments extend beyond its own facilities to include emissions across the value chain. Its FY2030 targets include a 42% reduction in Scope 1 and 2 emissions and a 25% reduction in Scope 3 emissions, against the FY2022 baseline.

During FY2025-26, the Company achieved a 22.6% reduction in Scope 1 and 2 emissions against the baseline. It also sourced 41% of its total energy consumption from renewable sources.

These results reflect progress towards its climate commitments and reinforce the importance of connecting operational performance with broader supply chain sustainability objectives.

Working with Suppliers

Building a sustainable supplier ecosystem requires more than setting expectations. It also involves helping business partners understand requirements, strengthen capabilities and make progress towards shared goals.

Piramal Pharma has focused on supplier engagement through training, assessments and capability-building initiatives. Its programmes have included sustainability training for more than 180 participants across over 120 suppliers, alongside more than 170 supplier assessments.

The Company has also conducted workshops covering quality, regulatory and ESG capabilities. These engagements encourage suppliers to strengthen their own practices and contribute to a more responsible value chain.

By combining clear standards with assessment and capacity building, Piramal Pharma aims to make sustainability an ongoing part of supplier relationships. More information is available on the Responsible Supply Chain at Piramal Pharma page.

What Are the First Steps for a Pharma Company?

Building a sustainable pharmaceutical supply chain requires a structured approach that combines clear expectations with ongoing monitoring and collaboration. While the priorities may differ across organisations, four steps can help establish a strong foundation:

  1. Map the supplier network: Identify key suppliers, sourcing locations, materials and services to understand where environmental, social and operational risks may arise.
  2. Establish a code of conduct: Define clear expectations covering environmental responsibility, labour practices, human rights, business ethics and regulatory compliance.
  3. Assess suppliers based on risk: Use structured assessments and appropriate audit mechanisms to identify gaps, prioritise critical suppliers and monitor progress.
  4. Measure and report progress: Establish relevant indicators, track performance over time and communicate progress transparently to customers, investors and other stakeholders.

These steps help move sustainability from a policy-level commitment to an integrated part of procurement and business decision-making.

Conclusion

A sustainable supply chain pharma strategy is an important part of building a stronger, more responsible and future-ready organisation. By improving supplier oversight, supporting credible climate commitments and strengthening customer confidence, companies can connect sustainability with long-term business priorities. Piramal Pharma's approach reflects this commitment through measurable targets, supplier engagement and continued progress across its value chain. Read more about the Company's sustainability priorities and progress in its latest Sustainability Report.

Frequently Asked Questions

How is a sustainable supply chain different from a resilient one?

A sustainable supply chain considers environmental, social and ethical impacts across the value chain. A resilient supply chain focuses on its ability to withstand disruptions and maintain continuity. The two are closely connected, as responsible supplier practices can support more dependable long-term relationships.

What is PSCI and why do pharma companies use it?

The Pharmaceutical Supply Chain Initiative (PSCI) is an industry collaboration established in 2006 to promote responsible practices across pharmaceutical supply chains. Companies use its principles to encourage consistent expectations and improve environmental, social and ethical performance among suppliers.

Does a sustainable supply chain cost more?

Some elements, such as supplier assessments, training and emissions data collection, can involve additional upfront costs. The business case also considers the value of better risk management, stronger supplier relationships and more consistent supply. The financial benefits should be assessed over time rather than assumed.

How can a supplier work with Piramal Pharma?

Potential suppliers can start with the “Become a Piramal Pharma Supplier” section of the responsible supply chain page, which lists the categories Piramal sources and the Supplier Expression of Interest process.

  • Facebook
  • Linkedin
  • Twitter X
  • WhatsApp

Latest Blogs

How Piramal Pharma Supports Women at Work: Benefits, Flexibility, and Leadership Development

06.11.2026

How Piramal Pharma Supports Women at Work: Benefits, Flexibility, and Leadership Development

For women building careers in pharma, choosing an employer isn’t just about salary and title. The real question is whether the organization will invest in their growth.

Read More: How Piramal Pharma Supports Women at Work: Benefits, Flexibility, and Leadership Development
How Global Pharma Companies Navigate Uncertainty

03.11.2026

How Global Pharma Companies Navigate Uncertainty

Global pharma companies navigate pharmaceutical industry challenges by building resilience into regulation and quality, supply networks

Read More: How Global Pharma Companies Navigate Uncertainty
Vertical API Integration: How Piramal Pharma Builds Supply Chain Resilience for Global Clients

23.10.2026

Vertical API Integration: How Piramal Pharma Builds Supply Chain Resilience for Global Clients

The pharmaceutical supply chain has never faced a stress test quite like this one.

Read More: Vertical API Integration: How Piramal Pharma Builds Supply Chain Resilience for Global Clients